FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
US6995008B1
(en)
*
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5736524A
(en)
*
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6338852B1
(en)
|
1995-09-01 |
2002-01-15 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6592877B1
(en)
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6290969B1
(en)
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US20070021364A1
(en)
*
|
1995-12-13 |
2007-01-25 |
Hans Herweijer |
Methods for genetic immunization
|
US20020165183A1
(en)
*
|
1999-11-29 |
2002-11-07 |
Hans Herweijer |
Methods for genetic immunization
|
ZA973642B
(en)
*
|
1996-04-26 |
1997-11-25 |
Merck & Co Inc |
DNA vaccine formulations.
|
US5846946A
(en)
*
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
FR2751225B1
(fr)
*
|
1996-07-19 |
1998-11-27 |
Rhone Merieux |
Formule de vaccin polynucleotidique aviaire
|
FR2751228B1
(fr)
*
|
1996-07-19 |
1998-11-20 |
Rhone Merieux |
Vaccin polynucleotidique bovin pour voie intradermique
|
EP2298900A1
(en)
*
|
1996-09-17 |
2011-03-23 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating intracellular diseases
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
AU6148798A
(en)
*
|
1997-02-07 |
1998-08-26 |
Vanderbilt University |
Synthetic genes for recombinant mycobacterium proteins
|
US6261281B1
(en)
*
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
AU3489499A
(en)
*
|
1998-04-14 |
1999-11-01 |
Merck & Co., Inc. |
Needleless administration of polynucleotide formulations
|
BR9915055A
(pt)
*
|
1998-11-04 |
2001-08-07 |
Isis Innovation |
Teste diagnóstico de tuberculose
|
US8197461B1
(en)
|
1998-12-04 |
2012-06-12 |
Durect Corporation |
Controlled release system for delivering therapeutic agents into the inner ear
|
US6465633B1
(en)
|
1998-12-24 |
2002-10-15 |
Corixa Corporation |
Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
|
AU3593200A
(en)
*
|
1999-02-09 |
2000-08-29 |
Powderject Vaccines, Inc. |
(mycobacterium tuberculosis), immunization
|
CA2368655A1
(en)
*
|
1999-04-08 |
2000-10-19 |
Gregory M. Glenn |
Dry formulation for transcutaneous immunization
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
US6545127B1
(en)
*
|
1999-06-28 |
2003-04-08 |
Oklahoma Medical Research Foundation |
Catalytically active recombinant memapsin and methods of use thereof
|
US6514948B1
(en)
*
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
US20050100928A1
(en)
*
|
1999-09-16 |
2005-05-12 |
Zycos Inc., A Delaware Corporation |
Nucleic acids encoding polyepitope polypeptides
|
WO2001032901A1
(en)
*
|
1999-11-01 |
2001-05-10 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
AU1661201A
(en)
|
1999-11-18 |
2001-05-30 |
Epimmune, Inc. |
Heteroclitic analogs and related methods
|
US20020051791A1
(en)
*
|
1999-12-22 |
2002-05-02 |
Galloway Darrel R. |
Methods for protection against lethal infection with bacillus anthracis
|
FR2804028B1
(fr)
*
|
2000-01-21 |
2004-06-04 |
Merial Sas |
Vaccins adn ameliores pour animaux de rente
|
EP1253947A4
(en)
*
|
2000-01-31 |
2005-01-05 |
Univ California |
IMMUNOMODULATED POLYNUCLEOTIDES FOR THE TREATMENT OF INFECTIONS BY INTRA-CELLULAR DISEASES
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
WO2001062207A2
(en)
*
|
2000-02-23 |
2001-08-30 |
The Regents Of The University Of California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
EP1278541A1
(en)
*
|
2000-04-28 |
2003-01-29 |
The Government of The United States of America, as represented by The Department of Health and Human Services |
Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
|
US6590087B1
(en)
*
|
2000-05-25 |
2003-07-08 |
Johns Hopkins University |
whmD, an essential cell division gene from mycobacteria
|
AU2001271963A1
(en)
*
|
2000-07-10 |
2002-01-21 |
Colorado State University Research Foundation |
Mid-life vaccine and methods for boosting anti-mycobacterial immunity
|
DK1299727T3
(da)
|
2000-07-12 |
2009-06-15 |
Agensys Inc |
Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
|
AU8846601A
(en)
|
2000-08-28 |
2002-03-13 |
Agensys Inc |
Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
ATE536187T1
(de)
|
2000-10-19 |
2011-12-15 |
Epimmune Inc |
Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
DK1372708T3
(da)
*
|
2001-02-13 |
2008-10-20 |
Us Gov Sec Army |
Vaccine til transkutan immunisering mod rejsediarre
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
WO2002080849A2
(en)
*
|
2001-04-06 |
2002-10-17 |
University Of Chicago |
Chemotherapeutic induction of egr-1 promoter activity
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
AU2002318112B2
(en)
|
2001-04-10 |
2007-12-06 |
Agensys, Inc. |
Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
US7013940B2
(en)
*
|
2001-04-19 |
2006-03-21 |
Michelin Recherche Et Technique S.A. |
Device for attenuating cavity noise in a tire and wheel
|
US7452705B2
(en)
|
2001-05-22 |
2008-11-18 |
The University Of Chicago |
N4 virion single-stranded DNA dependent RNA polymerase
|
WO2003015716A2
(en)
*
|
2001-08-13 |
2003-02-27 |
Ige Therapeutics, Inc. |
Immunoglobulin e vaccines and methods of use thereof
|
ES2532757T3
(es)
|
2001-09-06 |
2015-03-31 |
Agensys, Inc. |
Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
|
WO2003038112A2
(en)
|
2001-10-26 |
2003-05-08 |
Baylor College Of Medicine |
A composition and method to alter lean body mass and bone properties in a subject
|
AR037778A1
(es)
|
2001-12-11 |
2004-12-01 |
Advisys Inc |
Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos
|
EP1470161A1
(en)
*
|
2002-01-18 |
2004-10-27 |
Inovio AS |
Bispecific antibody dna constructs for intramuscular administration
|
US20050267025A1
(en)
*
|
2002-02-01 |
2005-12-01 |
Ho John L |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20040014956A1
(en)
|
2002-02-01 |
2004-01-22 |
Sequitur, Inc. |
Double-stranded oligonucleotides
|
AU2003210818A1
(en)
*
|
2002-02-01 |
2003-09-02 |
Cornell Research Foundation, Inc. |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20060009409A1
(en)
*
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
EP1572902B1
(en)
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
EP2258712A3
(en)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
US20050222060A1
(en)
*
|
2002-03-15 |
2005-10-06 |
Bot Adrian L |
Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
US7078037B2
(en)
*
|
2002-04-19 |
2006-07-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
|
WO2004041997A2
(en)
*
|
2002-05-01 |
2004-05-21 |
National Institutes Of Health |
Immunotherapy regimens in hiv-infected patients
|
CN100418981C
(zh)
|
2002-06-10 |
2008-09-17 |
瓦西尼斯公司 |
在乳腺癌和膀胱癌中差异表达的基因及编码多肽
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US20050175625A1
(en)
*
|
2002-07-12 |
2005-08-11 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
CA2501188C
(en)
|
2002-07-15 |
2012-05-15 |
Board Of Regents, The University Of Texas System |
Combinatorial protein library screening by periplasmic expression
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
EP2269618A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
|
AU2003243151A1
(en)
|
2002-08-16 |
2004-03-03 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
ATE465753T1
(de)
*
|
2002-10-21 |
2010-05-15 |
Eisai Inc |
Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
|
EP1565200A4
(en)
|
2002-11-27 |
2009-06-24 |
Agensys Inc |
NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
|
EP1903056A3
(en)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
|
CA2860151A1
(en)
|
2003-02-10 |
2004-08-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
CN1795274A
(zh)
*
|
2003-03-26 |
2006-06-28 |
多单元免疫治疗公司 |
诱导细胞死亡和/或凋亡的选定的rna基序
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
WO2004105681A2
(en)
*
|
2003-04-28 |
2004-12-09 |
Innogenetics N.V. |
Cd4+ human papillomavirus (hpv) epitopes
|
SI1629088T1
(sl)
|
2003-05-30 |
2012-08-31 |
Agensys Inc |
Antigen izvornih celic prostate (psca) in njegova podzaporedja
|
WO2004110482A1
(en)
*
|
2003-06-13 |
2004-12-23 |
Isis Innovation Limited |
Improved vaccines
|
US20070224615A1
(en)
*
|
2003-07-09 |
2007-09-27 |
Invitrogen Corporation |
Methods for assaying protein-protein interactions
|
WO2005007822A2
(en)
|
2003-07-09 |
2005-01-27 |
Sentigen Biosciences, Inc. |
Method for assaying protein-protein interaction
|
CA2536735C
(en)
*
|
2003-09-05 |
2013-01-22 |
Genencor International, Inc. |
Methods for determining cd8+ t-cell epitopes
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
ES2387850T3
(es)
*
|
2004-02-11 |
2012-10-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. |
Proteína de fusión al antígeno carcinoembrionario y sus usos
|
EP1735435A1
(en)
*
|
2004-03-18 |
2006-12-27 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving s-ship promoter regions
|
EP2583981A3
(en)
|
2004-05-28 |
2013-07-31 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
US20090221440A1
(en)
*
|
2004-07-12 |
2009-09-03 |
Board Of Regents, The University Of Texas System |
Methods and compositions related to identifying protein-protein interactions
|
US7572600B2
(en)
|
2004-08-04 |
2009-08-11 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
DK2302055T3
(da)
|
2004-11-12 |
2014-10-13 |
Asuragen Inc |
Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
|
KR101255870B1
(ko)
|
2004-11-16 |
2013-04-17 |
아에라스 글로벌 티비 백신 파운데이션 |
재조합 바이러스 벡터를 포함하는 다가 백신
|
AU2005312062B2
(en)
*
|
2004-12-01 |
2011-11-17 |
Aeras Global Tb Vaccine Foundation |
Electroporation of Mycobacterium and overexpression of antigens in Mycobacteria
|
JP2008538894A
(ja)
*
|
2005-02-11 |
2008-11-13 |
メルク エンド カムパニー インコーポレーテッド |
アデノウイルス血清型26ベクター、核酸およびそれにより製造されたウイルス
|
EP2325306B1
(en)
|
2005-02-25 |
2014-02-12 |
Oncotherapy Science, Inc. |
Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
|
ES2442294T3
(es)
|
2005-02-28 |
2014-02-11 |
Oncotherapy Science, Inc. |
Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos
|
EP1863848A4
(en)
|
2005-03-31 |
2009-09-23 |
Agensys Inc |
CORRESPONDING ANTIBODIES AND MOLECULES THAT ATTACH PROTEINS 161P2F10B
|
EP1912675B1
(en)
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
HUE027330T2
(en)
|
2005-07-27 |
2016-09-28 |
Oncotherapy Science Inc |
The TOM34 gene for colon cancer
|
AU2006279896A1
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating Alzheimer's disease
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
KR20090004839A
(ko)
*
|
2005-09-07 |
2009-01-12 |
제네렉스, 인코포레이티드 |
Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
|
US7919258B2
(en)
*
|
2005-10-07 |
2011-04-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Rapid tuberculosis detection method
|
EP2368569A3
(en)
|
2006-01-18 |
2012-05-02 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
BRPI0708865A8
(pt)
*
|
2006-03-14 |
2019-01-22 |
Univ Oregon Health & Science |
métodos para produzir uma resposta imune à tuberculose
|
GB0605474D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Isis Innovation |
Clinical correlates
|
US8409577B2
(en)
|
2006-06-12 |
2013-04-02 |
Emergent Product Development Seattle, Llc |
Single chain multivalent binding proteins with effector function
|
EP2069791B1
(en)
|
2006-07-27 |
2012-01-25 |
University of Maryland, Baltimore |
Cellular receptor for antiproliferative factor
|
EP2839837B1
(en)
|
2006-09-15 |
2019-05-08 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Oncolytic farmington rhabdovirus
|
CN102850434B
(zh)
|
2006-10-17 |
2016-04-13 |
肿瘤疗法科学股份有限公司 |
用于表达mphosph1或depdc1多肽的癌症的肽疫苗
|
US8753840B2
(en)
*
|
2006-10-20 |
2014-06-17 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Modified cyanobacteria
|
CA2671264C
(en)
|
2006-11-30 |
2015-11-24 |
Research Development Foundation |
Improved immunoglobulin libraries
|
TWI615403B
(zh)
|
2007-02-21 |
2018-02-21 |
腫瘤療法 科學股份有限公司 |
表現腫瘤相關抗原之癌症的胜肽疫苗
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
TW201425333A
(zh)
|
2007-04-11 |
2014-07-01 |
Oncotherapy Science Inc |
腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
|
AU2008247819B2
(en)
|
2007-05-01 |
2013-02-14 |
Research Development Foundation |
Immunoglobulin Fc libraries
|
US20090148447A1
(en)
*
|
2007-07-06 |
2009-06-11 |
Trubion Pharmaceuticals, Inc. |
Binding Peptides Having a C-terminally Disposed Specific Binding Domain
|
CN101951948B
(zh)
|
2007-08-31 |
2015-12-09 |
芝加哥大学 |
与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物
|
EP2215111B1
(en)
|
2007-11-01 |
2016-03-16 |
Mayo Foundation For Medical Education And Research |
Hla-dr binding peptides and their uses
|
EP2944649A1
(en)
|
2008-01-10 |
2015-11-18 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
JP2011510308A
(ja)
*
|
2008-01-23 |
2011-03-31 |
リグスホスピタル |
バイオマーカーykl−40のレベルの測定により見出される生存予後に基く心血管疾患を患う個体の分類
|
BRPI0907637A8
(pt)
|
2008-01-25 |
2018-01-02 |
P53 Inc |
biomarcadores p53
|
EP2955222B1
(en)
|
2008-03-17 |
2018-09-12 |
The Scripps Research Institute |
Combined chemical and genetic approaches for generation of induced pluripotent stem cells
|
WO2009117134A2
(en)
*
|
2008-03-21 |
2009-09-24 |
National Institutes Of Health |
Aerosolized genetic vaccines and methods of use
|
JP6013733B2
(ja)
*
|
2008-04-11 |
2016-10-25 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
EP2288379A4
(en)
|
2008-05-19 |
2012-08-08 |
Advaxis |
DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
KR101871192B1
(ko)
|
2008-06-04 |
2018-06-27 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
비-바이러스 접근법을 사용한 iPS 세포의 생산 방법
|
US8299232B2
(en)
*
|
2008-07-25 |
2012-10-30 |
Department Of Biotechnology |
Constructing a DNA chimera for vaccine development against leishmaniasis and tuberculosis
|
CN107988261A
(zh)
|
2008-08-12 |
2018-05-04 |
细胞动力国际有限公司 |
产生ips细胞的方法
|
EP2328603A4
(en)
|
2008-08-18 |
2013-01-02 |
Univ Maryland |
APF DERIVATIVES AND USE METHOD
|
JP5764822B2
(ja)
|
2008-08-27 |
2015-08-19 |
オンコセラピー・サイエンス株式会社 |
がんの治療および診断の標的遺伝子としてのprmt1
|
BRPI0920041A2
(pt)
|
2008-10-06 |
2017-06-27 |
Univ Chicago |
composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
|
US8784829B2
(en)
*
|
2008-10-23 |
2014-07-22 |
Intervet Inc. |
Lawsonia intracellularis vaccines
|
TWI539160B
(zh)
|
2008-12-05 |
2016-06-21 |
腫瘤療法 科學股份有限公司 |
Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
|
US9084781B2
(en)
|
2008-12-10 |
2015-07-21 |
Novartis Ag |
MEK mutations conferring resistance to MEK inhibitors
|
BRPI0922572A2
(pt)
|
2008-12-17 |
2019-09-24 |
Scripps Research Inst |
método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
|
WO2010084488A1
(en)
|
2009-01-20 |
2010-07-29 |
Ramot At Tel-Aviv University Ltd. |
Mir-21 promoter driven targeted cancer therapy
|
TWI469791B
(zh)
|
2009-02-18 |
2015-01-21 |
Oncotherapy Science Inc |
Foxm1胜肽以及含此胜肽之疫苗
|
ES2617434T3
(es)
|
2009-03-18 |
2017-06-19 |
Oncotherapy Science, Inc. |
Péptidos NEIL3 y vacunas que incluyen los mismos
|
EP3281947B1
(en)
|
2009-04-03 |
2020-02-12 |
The University of Chicago |
Compositions and methods related to protein a (spa) variants
|
EP2424885B1
(en)
|
2009-04-28 |
2016-03-23 |
Vanderbilt University |
Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
|
TWI507204B
(zh)
|
2009-05-26 |
2015-11-11 |
Oncotherapy Science Inc |
Cdc45l胜肽與含此胜肽之疫苗
|
KR101811235B1
(ko)
|
2009-06-05 |
2017-12-21 |
셀룰러 다이내믹스 인터내셔널, 인코포레이티드 |
T 세포 및 조혈 세포의 재프로그래밍
|
US20110053803A1
(en)
|
2009-08-26 |
2011-03-03 |
Xin Ge |
Methods for creating antibody libraries
|
BR112012005774B8
(pt)
|
2009-09-14 |
2023-02-14 |
Jennerex Inc |
uso de um inibidor de quinase antiangiogênico no tratamento de câncer
|
EP2480572B1
(en)
|
2009-09-25 |
2019-01-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 and their use
|
JP2013506682A
(ja)
*
|
2009-09-30 |
2013-02-28 |
セント ルイス ユニバーシティ |
異種亜型インフルエンザt細胞応答を誘発するためのペプチド
|
ES2938049T3
(es)
|
2009-10-16 |
2023-04-04 |
Scripps Research Inst |
Inducción de células pluripotentes
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
MX337062B
(es)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Rabdovirus oncolítico.
|
TW201136604A
(en)
|
2009-12-14 |
2011-11-01 |
Oncotherapy Science Inc |
TMEM22 peptides and vaccines including the same
|
US10080799B2
(en)
|
2010-02-12 |
2018-09-25 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions related to glycoprotein-immunoglobulin fusions
|
EP3028699B1
(en)
|
2010-02-25 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
WO2011106705A2
(en)
|
2010-02-26 |
2011-09-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Dna-protein vaccination protocols
|
EP2542678B1
(en)
|
2010-03-04 |
2017-04-12 |
InteRNA Technologies B.V. |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
|
KR101872284B1
(ko)
|
2010-03-11 |
2018-06-28 |
온코세라피 사이언스 가부시키가이샤 |
Hjurp 펩티드 및 이를 포함한 백신
|
WO2011123572A1
(en)
|
2010-03-31 |
2011-10-06 |
The Scripps Research Institute |
Reprogramming cells
|
TW201627003A
(zh)
|
2010-04-02 |
2016-08-01 |
腫瘤療法 科學股份有限公司 |
Ect2胜肽及含此胜肽之疫苗
|
US8808699B2
(en)
|
2010-04-05 |
2014-08-19 |
The University Of Chicago |
Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
|
WO2011126976A1
(en)
|
2010-04-07 |
2011-10-13 |
Vanderbilt University |
Reovirus vaccines and methods of use therefor
|
DK2560672T3
(en)
|
2010-04-19 |
2014-03-17 |
Res Dev Foundation |
RTEF-1 variants and their uses
|
EP3889254B1
(en)
|
2010-06-09 |
2024-08-14 |
Dana-Farber Cancer Institute, Inc. |
A mek1 mutation conferring resistance to raf and mek inhibitors
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
KR101861168B1
(ko)
|
2010-06-15 |
2018-05-31 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
작은 부피의 말초 혈액으로부터의 유도된 만능 줄기 세포의 생성
|
CA2802087A1
(en)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
A compendium of ready-built stem cell models for interrogation of biological response
|
SG186290A1
(en)
|
2010-07-02 |
2013-01-30 |
Univ Chicago |
Compositions and methods related to protein a (spa) variants
|
NZ704322A
(en)
|
2010-07-06 |
2016-07-29 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
JP5897002B2
(ja)
|
2010-07-07 |
2016-04-13 |
セルラー ダイナミクス インターナショナル, インコーポレイテッド |
プログラミングによる内皮細胞の産生
|
WO2012018933A2
(en)
|
2010-08-04 |
2012-02-09 |
Cellular Dynamics International, Inc. |
Reprogramming immortalized b cells
|
EP2614074A1
(en)
|
2010-09-09 |
2013-07-17 |
The University of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
CN105457016B
(zh)
|
2010-09-22 |
2022-06-24 |
科罗拉多大学董事会 |
Smad7的治疗应用
|
CN107412756A
(zh)
|
2010-10-01 |
2017-12-01 |
宾夕法尼亚大学理事会 |
李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
|
EP2622065B1
(en)
|
2010-10-01 |
2016-09-07 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Manipulation of stem cell function by p53 isoforms
|
JP6182456B2
(ja)
|
2010-12-22 |
2017-08-23 |
フェイト セラピューティクス,インコーポレイテッド |
単細胞選別のための細胞培養プラットホームおよびiPSCの再プログラミングの増強
|
CN103429258B
(zh)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
RU2539035C2
(ru)
*
|
2011-01-13 |
2015-01-10 |
Амир Закиевич Максютов |
Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов
|
CA2826467C
(en)
|
2011-02-07 |
2019-11-12 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides
|
EP2673358B1
(en)
|
2011-02-08 |
2019-01-09 |
FUJIFILM Cellular Dynamics, Inc. |
Hematopoietic precursor cell production by programming
|
EP3332804A1
(en)
|
2011-03-11 |
2018-06-13 |
Advaxis, Inc. |
Listeria-based adjuvants
|
EP2694534B1
(en)
|
2011-04-08 |
2018-06-20 |
Evaxion Biotech ApS |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
WO2012156535A1
(en)
|
2011-05-19 |
2012-11-22 |
Fundación Progreso Y Salud |
Highly inducible dual-promoter lentiviral tet-on system
|
CA2872045A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
US20130040302A1
(en)
|
2011-07-11 |
2013-02-14 |
Thomas J. Burke |
Methods for cell reprogramming and genome engineering
|
DK2738255T3
(en)
|
2011-07-29 |
2017-03-06 |
Univ Tokushima |
ERAP1-Derived Peptide and its Use
|
MX350220B
(es)
|
2011-08-12 |
2017-08-30 |
Oncotherapy Science Inc |
Peptidos de mphosph1 y vacunas que incluyen los mismos.
|
EP2744517B1
(en)
|
2011-08-15 |
2019-03-13 |
The University of Chicago |
Compositions and methods related to antibodies to staphylococcal protein a
|
US20130101664A1
(en)
|
2011-08-18 |
2013-04-25 |
Donald W. Kufe |
Muc1 ligand traps for use in treating cancers
|
JP2013046596A
(ja)
*
|
2011-08-29 |
2013-03-07 |
Alpha-Nano-Medica Co Ltd |
新規な複合体、それを含有する医薬及び癌の治療方法
|
WO2013053899A1
(en)
|
2011-10-12 |
2013-04-18 |
Moeller Niels Iversen |
Peptides derived from campylobacter jejuni and their use in vaccination
|
IN2014CN03922A
(pt)
|
2011-10-28 |
2015-09-04 |
Oncotherapy Science Inc |
|
ES2886147T3
(es)
|
2011-12-22 |
2021-12-16 |
Interna Tech B V |
MiARN para el tratamiento del cáncer de cabeza y de cuello
|
EP2825195A4
(en)
|
2012-03-12 |
2015-10-07 |
Advaxis Inc |
INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
|
CN104703622B
(zh)
|
2012-04-26 |
2017-05-24 |
芝加哥大学 |
与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
|
US9968668B2
(en)
|
2012-04-26 |
2018-05-15 |
The University Of Chicago |
Staphylococcal coagulase antigens and methods of their use
|
WO2014010232A1
(en)
|
2012-07-10 |
2014-01-16 |
Oncotherapy Science, Inc. |
Ly6k epitope peptides for th1 cells and vaccines containing the same
|
JP6259983B2
(ja)
|
2012-07-10 |
2018-01-17 |
オンコセラピー・サイエンス株式会社 |
Th1細胞のKIF20Aエピトープペプチドおよびこれを含有するワクチン
|
EP2895600B1
(en)
|
2012-09-11 |
2020-02-19 |
OncoTherapy Science, Inc. |
Ube2t peptides and vaccines containing the same
|
EP2912058A1
(en)
|
2012-10-23 |
2015-09-02 |
The Board of Regents of The University of Texas System |
Antibodies with engineered igg fc domains
|
US10201556B2
(en)
|
2012-11-06 |
2019-02-12 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
|
WO2014116721A1
(en)
|
2013-01-22 |
2014-07-31 |
The Arizona Board Of Regents For And On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
BR112015019950B1
(pt)
|
2013-02-20 |
2023-02-14 |
Regeneron Pharmaceuticals, Inc |
Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro
|
CA2901501C
(en)
|
2013-02-21 |
2023-03-07 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
WO2014130770A1
(en)
|
2013-02-22 |
2014-08-28 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
US10086093B2
(en)
|
2013-02-28 |
2018-10-02 |
The General Hospital Corporation |
miRNA profiling compositions and methods of use
|
US10456448B2
(en)
|
2013-03-08 |
2019-10-29 |
The Regents Of The University Of Colorado, A Body Corporate |
PTD-SMAD7 therapeutics
|
TWI658049B
(zh)
|
2013-03-12 |
2019-05-01 |
腫瘤療法 科學股份有限公司 |
Kntc2胜肽及含此胜肽之疫苗
|
WO2014140301A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Université De Genève |
Anti-mycobacterial vaccines
|
US10022441B2
(en)
|
2013-03-27 |
2018-07-17 |
Immunovaccine Technologies, Inc. |
Method for improving the efficacy of a survivin vaccine in the treatment of cancer
|
RU2520078C1
(ru)
*
|
2013-04-25 |
2014-06-20 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) |
СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
|
JP2016531147A
(ja)
|
2013-09-09 |
2016-10-06 |
フィジーン、エルエルシーFigene, Llc |
コンドロサイトまたは軟骨型細胞の再生のための遺伝子治療
|
WO2015070050A1
(en)
|
2013-11-08 |
2015-05-14 |
Baylor Research Institute |
Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
US20170002064A1
(en)
|
2013-11-08 |
2017-01-05 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
EP4227685A3
(en)
|
2013-12-03 |
2024-02-28 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
EP3099719B1
(en)
|
2014-01-29 |
2020-04-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
|
US10214741B2
(en)
|
2014-02-14 |
2019-02-26 |
University Of Utah Research Foundation |
Methods and compositions for inhibiting retinopathy of prematurity
|
EP3110836A1
(en)
|
2014-02-25 |
2017-01-04 |
Research Development Foundation |
Sty peptides for inhibition of angiogenesis
|
EP3604499A1
(en)
|
2014-03-04 |
2020-02-05 |
Fate Therapeutics, Inc. |
Improved reprogramming methods and cell culture platforms
|
US20170107486A1
(en)
|
2014-04-21 |
2017-04-20 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
RU2700881C2
(ru)
|
2014-08-04 |
2019-09-23 |
Онкотерапи Сайенс, Инк. |
Пептид, полученный из urlc10, и содержащая его вакцина
|
BR112017002212A2
(pt)
|
2014-08-04 |
2017-11-21 |
Oncotherapy Science Inc |
peptídeo derivado de cdca1 e vacina contendo o mesmo
|
BR112017002206A2
(pt)
|
2014-08-04 |
2017-11-21 |
Oncotherapy Science Inc |
peptídeo derivado de koc1 e vacina incluindo o mesmo
|
US20180363070A9
(en)
|
2014-08-12 |
2018-12-20 |
Univ Wayne State |
Systems and methods to detect stem cell stress and uses thereof
|
EP3218002B1
(en)
|
2014-11-13 |
2020-08-19 |
Evaxion Biotech ApS |
Peptides derived from acinetobacter baumannii and their use in vaccination
|
CN107531736B
(zh)
|
2015-01-06 |
2022-04-15 |
免疫疫苗科技公司 |
脂质a模拟物、其制备方法和用途
|
EP3244918A2
(en)
|
2015-01-12 |
2017-11-22 |
Evaxion Biotech ApS |
Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae
|
US20180002656A1
(en)
|
2015-01-28 |
2018-01-04 |
Sabic Global Technologies B.V. |
Methods and compositions for high-efficiency production of biofuel and/or biomass
|
EP3256490A1
(en)
|
2015-02-09 |
2017-12-20 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
EP3259346B1
(en)
|
2015-02-20 |
2024-08-07 |
Baylor College of Medicine |
P63 inactivation for the treatment of heart failure
|
EP3294755B1
(en)
|
2015-05-13 |
2023-08-23 |
The United States of America as represented by the Secretary of the Department of Health and Human Services |
Methods and compositions for inducing an immune response using conserved element constructs
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
WO2017005670A1
(en)
|
2015-07-04 |
2017-01-12 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
KR20180053322A
(ko)
|
2015-09-21 |
2018-05-21 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
RU2738418C2
(ru)
|
2015-10-08 |
2020-12-14 |
Онкотерапи Сайенс, Инк. |
Пептид, полученный из foxm1, и включающая его вакцина
|
US11441126B2
(en)
|
2015-10-16 |
2022-09-13 |
Fate Therapeutics, Inc. |
Platform for the induction and maintenance of ground state pluripotency
|
WO2017070333A1
(en)
|
2015-10-20 |
2017-04-27 |
Cellular Dynamics International, Inc. |
Multi-lineage hematopoietic precursor cell production by genetic programming
|
TW202344686A
(zh)
|
2015-10-30 |
2023-11-16 |
美國加利福尼亞大學董事會 |
從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
|
LT3370733T
(lt)
|
2015-11-02 |
2021-10-25 |
Board Of Regents, The University Of Texas System |
Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
|
JP2018532810A
(ja)
|
2015-11-07 |
2018-11-08 |
マルチビア インコーポレイテッド |
がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
|
FI3373968T3
(fi)
|
2015-11-09 |
2024-07-17 |
Childrens Hospital Philadelphia |
Glypikaani 2 syövän merkkiaineena ja terapeuttisena kohteena
|
EP3419654B1
(en)
|
2016-02-22 |
2022-04-27 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
US20190177391A1
(en)
|
2016-03-31 |
2019-06-13 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
WO2017216384A1
(en)
|
2016-06-17 |
2017-12-21 |
Evaxion Biotech Aps |
Vaccination targeting ichthyophthirius multifiliis
|
CN109843321A
(zh)
*
|
2016-06-22 |
2019-06-04 |
国际艾滋病疫苗行动组织公司 |
作为结核病疫苗的重组巨细胞病毒载体
|
WO2017220787A1
(en)
|
2016-06-24 |
2017-12-28 |
Evaxion Biotech Aps |
Vaccines against aearomonas salmonicida infection
|
JP7099967B2
(ja)
|
2016-07-01 |
2022-07-12 |
リサーチ ディベロップメント ファウンデーション |
幹細胞由来移植片からの増殖性細胞の排除
|
US11414464B2
(en)
|
2016-07-22 |
2022-08-16 |
Evaxion Biotech A/S |
Chimeric proteins for inducing immunity towards infection with S. aureus
|
WO2018035429A1
(en)
|
2016-08-18 |
2018-02-22 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
|
CN109963590B
(zh)
|
2016-09-02 |
2024-03-15 |
加利福尼亚大学董事会 |
涉及白介素-6受体α结合单链可变片段的方法和组合物
|
WO2018067836A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Methods for directed differentiation of pluripotent stem cells to hla homozygous immune cells
|
EP3523422A1
(en)
|
2016-10-05 |
2019-08-14 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
WO2018127545A1
(en)
|
2017-01-05 |
2018-07-12 |
Evaxion Biotech Aps |
Vaccines targeting pseudomonas aeruginosa
|
BR112019021745A2
(pt)
|
2017-04-18 |
2020-05-05 |
Fujifilm Cellular Dynamics Inc |
células efetoras imunológicas antígeno-específicas
|
EP3704250A1
(en)
|
2017-11-03 |
2020-09-09 |
InteRNA Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
WO2019099493A1
(en)
|
2017-11-14 |
2019-05-23 |
Henry Ford Health System |
Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
|
BR112020013715A2
(pt)
|
2018-01-05 |
2020-12-01 |
Ottawa Hospital Research Institute |
vetores de vaccinia modificados
|
WO2019145399A1
(en)
|
2018-01-24 |
2019-08-01 |
Evaxion Biotech Aps |
Vaccines for prophylaxis of s. aureus infections
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
CA3133899A1
(en)
|
2018-03-30 |
2019-10-03 |
University Of Geneva |
Micro rna expression constructs and uses thereof
|
TW202023581A
(zh)
|
2018-08-02 |
2020-07-01 |
日商腫瘤療法 科學股份有限公司 |
來自cdca1的胜肽及含有此的疫苗
|
JP7450945B2
(ja)
|
2018-08-30 |
2024-03-18 |
テナヤ セラピューティクス, インコーポレイテッド |
ミオカルディンおよびascl1を用いた心細胞リプログラミング
|
US20220000932A1
(en)
|
2018-09-28 |
2022-01-06 |
Henry Ford Health System |
Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
|
WO2020083904A1
(en)
|
2018-10-22 |
2020-04-30 |
Evaxion Biotech Aps |
Vaccines targeting m. catharrhalis
|
JP7525855B2
(ja)
|
2018-11-30 |
2024-07-31 |
国立大学法人徳島大学 |
Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
US20220143168A1
(en)
|
2019-02-27 |
2022-05-12 |
Evaxion Biotech A/S |
Vaccines targeting H. influenzae
|
SG10201905939WA
(en)
|
2019-06-26 |
2021-01-28 |
Cell Mogrify Australia Pty Ltd |
Cell culture methods and compositions
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
AU2020317009A1
(en)
|
2019-07-19 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors containing Glypican 2 binding domains
|
CN115175680A
(zh)
|
2019-10-18 |
2022-10-11 |
加利福尼亚大学董事会 |
Plxdc激活剂及其用于治疗血管病症的用途
|
KR102237349B1
(ko)
|
2019-10-23 |
2021-04-07 |
한국과학기술연구원 |
니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
WO2021140123A1
(en)
|
2020-01-06 |
2021-07-15 |
Evaxion Biotech Aps |
Vaccines targeting neisseria gonorrhoeae
|
CN115552022A
(zh)
|
2020-03-02 |
2022-12-30 |
特纳亚治疗股份有限公司 |
由心肌细胞表达的微rna控制的基因载体
|
US20230211023A1
(en)
|
2020-03-25 |
2023-07-06 |
Erasmus University Medical Center Rotterdam |
Reporter system for radionuclide imaging
|
US20230242643A1
(en)
|
2020-05-27 |
2023-08-03 |
Antion Biosciences Sa |
Adapter molecules to re-direct car t cells to an antigen of interest
|
US20230201267A1
(en)
|
2020-05-29 |
2023-06-29 |
FUJIFILM Cellular Dynamics, Inc. |
Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
|
KR20230017876A
(ko)
|
2020-05-29 |
2023-02-06 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
망막 색소 상피 및 광수용체의 이중층 및 이의 용도
|
WO2022053130A1
(en)
|
2020-09-09 |
2022-03-17 |
Sid Alex Group, S.R.O. |
Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
|
WO2022173767A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Houston System |
Oncolytic virus for systemic delivery and enhanced anti-tumor activities
|
WO2022175815A1
(en)
|
2021-02-19 |
2022-08-25 |
Pfizer Inc. |
Methods of protecting rna
|
WO2022235586A1
(en)
|
2021-05-03 |
2022-11-10 |
Astellas Institute For Regenerative Medicine |
Methods of generating mature corneal endothelial cells
|
BR112023022181A2
(pt)
|
2021-05-07 |
2024-02-06 |
Astellas Inst For Regenerative Medicine |
Métodos de geração de hepatócitos maduros
|
EP4347796A1
(en)
|
2021-05-26 |
2024-04-10 |
Fujifilm Cellular Dynamics, Inc. |
Methods to prevent rapid silencing of genes in pluripotent stem cells
|
WO2023280807A1
(en)
|
2021-07-05 |
2023-01-12 |
Evaxion Biotech A/S |
Vaccines targeting neisseria gonorrhoeae
|
WO2023089556A1
(en)
|
2021-11-22 |
2023-05-25 |
Pfizer Inc. |
Reducing risk of antigen mimicry in immunogenic medicaments
|
WO2023144779A1
(en)
|
2022-01-28 |
2023-08-03 |
Pfizer Inc. |
Coronavirus antigen variants
|
WO2023178191A1
(en)
|
2022-03-16 |
2023-09-21 |
University Of Houston System |
Persistent hsv gene delivery system
|
GB202205265D0
(en)
|
2022-04-11 |
2022-05-25 |
Mogrify Ltd |
Cell conversion
|
WO2023213393A1
(en)
|
2022-05-04 |
2023-11-09 |
Evaxion Biotech A/S |
Staphylococcal protein variants and truncates
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2024006911A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Holdings America Corporation |
Ipsc-derived astrocytes and methods of use thereof
|
WO2024130212A1
(en)
|
2022-12-16 |
2024-06-20 |
Turnstone Biologics Corp. |
Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
|
WO2024186630A1
(en)
|
2023-03-03 |
2024-09-12 |
Henry Ford Health System |
Use of extracellular vesicles for the treatment of cancer
|